7MM sarcopenia market to see 8.1% CAGR growth until 2034

There are currently no approved drugs to treat the condition.

The sarcopenia sector across the seven major markets (7MM) is expected to expand at a compound annual growth rate of 8.1% until 2030, according to a DelveInsight report.

The market’s growth is attributed to the development of emerging therapies targeting various segments, such as liver cirrhosis, obesity, and chronic inflammation.

“There are currently no approved drugs to treat sarcopenia. Current approaches include resistance training, nutritional support, particularly adequate protein and vitamin D intake, and lifestyle modifications,” the report said.

The market is also driven by a high volume of patient population requiring treatment.

In 2024, the total number of diagnosed prevalent sarcopenia cases in the 7MM reached 19.8 million.

7MM = US, Germany, France, Italy, Spain, UK, and Japan.